Skip to main content
SpringerLink
Log in

CRT Devices in Heart Failure: Does the Patient Need a Pacemaker or Defibrillator?

  • Chapter
  • First Online:
Clinical Controversies in Device Therapy for Cardiac Arrhythmias

  • 248 Accesses

Abstract

Cardiac resynchronization therapy (CRT) can be delivered by either a CRT pacemaker (CRT-P) or a CRT defibrillator (CRT-D). No randomized control trial has ever been powered to compare the two device types; therefore cardiology society guidelines provide limited recommendations on choice of device. In this chapter we review the evidence for selecting a CRT-P or a CRT-D in individual patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.

    Article  Google Scholar 

  2. Authors/Task Force M, Priori SG, Blomstrom-Lundqvist C, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2015;17:1601–87.

    Google Scholar 

  3. Dickstein K, Normand C, Auricchio A, et al. CRT survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how? Eur J Heart Fail. 2018;20(6):1039–51.

    Article  Google Scholar 

  4. Normand CLC, Bogale N, et al. Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?—findings from the ESC CRT survey II. Europace. 2019;21(6):918–27.

    Article  Google Scholar 

  5. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34:2281–329.

    Article  Google Scholar 

  6. Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017;33:1342–433.

    Article  Google Scholar 

  7. NICE. Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120). guidance.nice.org.uk/ta314: NICE, 2014.

  8. Group NCHFGW, Atherton JJ, Sindone A, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. Heart Lung Circ. 2018;27:1123–208.

    Article  Google Scholar 

  9. Normand C, Linde C, Singh J, Dickstein K. Indications for cardiac resynchronization therapy: a comparison of the major international guidelines. JACC Heart Fail. 2018;6:308–16.

    Article  Google Scholar 

  10. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810–52.

    Article  Google Scholar 

  11. Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. [corrected]. Circulation. 2012;126:1784–800.

    Article  Google Scholar 

  12. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68:1476–88.

    Article  Google Scholar 

  13. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017;23:628–51.

    Article  Google Scholar 

  14. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.

    Article  CAS  Google Scholar 

  15. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.

    Article  Google Scholar 

  16. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.

    Article  CAS  Google Scholar 

  17. Ghio S, Freemantle N, Scelsi L, et al. Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail. 2009;11:480–8.

    Article  Google Scholar 

  18. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006;27:1928–32.

    Article  Google Scholar 

  19. Gold MR, Linde C, Abraham WT, Gardiwal A, Daubert JC. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm. 2011;8:679–84.

    Article  Google Scholar 

  20. Barsheshet A, Wang PJ, Moss AJ, et al. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2011;57:2416–23.

    Article  Google Scholar 

  21. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51:1357–65.

    Article  Google Scholar 

  22. Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014;35:1186–94.

    Article  Google Scholar 

  23. Chen Z, Kotecha T, Crichton S, et al. Lower incidence of inappropriate shock therapy in patients with combined cardiac resynchronisation therapy defibrillators (CRT-D) compared with patients with non-CRT defibrillators (ICDs). Int J Clin Pract. 2013;67:733–9.

    Article  CAS  Google Scholar 

  24. Schuchert A, Muto C, Maounis T, et al. Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker. Europace. 2013;15:71–6.

    Article  Google Scholar 

  25. Barra S, Providencia R, Boveda S, et al. Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention. Heart. 2018;104:1529–35.

    Article  Google Scholar 

  26. Stevenson LW, Desai AS. Selecting patients for discussion of the ICD as primary prevention for sudden death in heart failure. J Card Fail. 2006;12:407–12.

    Article  Google Scholar 

  27. Kutyifa V, Geller L, Bogyi P, et al. Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience. Eur J Heart Fail. 2014;16:1323–30.

    Article  Google Scholar 

  28. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.

    Article  CAS  Google Scholar 

  29. Barra S, Boveda S, Providencia R, et al. Adding defibrillation therapy to cardiac resynchronization on the basis of the myocardial substrate. J Am Coll Cardiol. 2017;69:1669–78.

    Article  Google Scholar 

  30. Leyva F, Zegard A, Umar F, et al. Long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy. Europace. 2018;20:1804–12.

    Article  Google Scholar 

  31. Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221–30.

    Article  Google Scholar 

  32. Doring M, Ebert M, Dagres N, et al. Cardiac resynchronization therapy in the ageing population – with or without an implantable defibrillator? Int J Cardiol. 2018;263:48–53.

    Article  Google Scholar 

  33. Marijon E, Leclercq C, Narayanan K, et al. Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study. Eur Heart J. 2015;36:2767–76.

    Article  CAS  Google Scholar 

  34. Drozd M, Gierula J, Lowry JE, et al. Cardiac resynchronization therapy outcomes in patients with chronic heart failure: cardiac resynchronization therapy with pacemaker versus cardiac resynchronization therapy with defibrillator. J Cardiovasc Med. 2017;18:962–7.

    Article  Google Scholar 

  35. Bastian D, Ebrahim IO, Chen JY et al. Real-world geographic variations in the use of cardiac implantable electronic devices-The PANORAMA 2 observational cohort study. Pacing Clin Electrophysiol (PACE). 2018;41(8):978–89.

    Article  Google Scholar 

  36. Lindvall C, Chatterjee NA, Chang Y, et al. National trends in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator. Circulation. 2016;133:273–81.

    Article  Google Scholar 

  37. Barra S, Providencia R, Duehmke R, et al. Cause-of-death analysis in patients with cardiac resynchronization therapy with or without a defibrillator: a systematic review and proportional meta-analysis. Europace. 2018;20:481–91.

    Article  Google Scholar 

  38. Munir MB, Althouse AD, Rijal S, et al. Clinical characteristics and outcomes of older cardiac resynchronization therapy recipients using a pacemaker versus a defibrillator. J Cardiovasc Electrophysiol. 2016;27:730–4.

    Article  Google Scholar 

  39. Barra S, Looi KL, Gajendragadkar PR, Khan FZ, Virdee M, Agarwal S. Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. Europace. 2016;18:1187–93.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Division, Stavanger University Hospital, Stavanger, Norway

    C. Normand & K. Dickstein

  2. Institute of Internal Medicine, University of Bergen, Bergen, Norway

    C. Normand & K. Dickstein

Authors
  1. C. Normand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Dickstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Dickstein .

Editor information

Editors and Affiliations

  1. University of Rochester School of Medicine & Dentistry/Hackensack Meridian, School of Medicine at Seton Hall, University/Summit Medical Group, Short Hills, NJ, USA

    Jonathan S. Steinberg

  2. Electrophysiology Section, Cardiovascular Division, Univeristy of Pennsylvania, and the Cardiology Division, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA

    Andrew E. Epstein

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Normand, C., Dickstein, K. (2019). CRT Devices in Heart Failure: Does the Patient Need a Pacemaker or Defibrillator?. In: Steinberg, J., Epstein, A. (eds) Clinical Controversies in Device Therapy for Cardiac Arrhythmias . Springer, Cham. https://doi.org/10.1007/978-3-030-22882-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-22882-8_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-22881-1

  • Online ISBN: 978-3-030-22882-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation